Keyphrases
Transient Elastography
66%
Chronic Hepatitis C
62%
Cirrhosis
54%
Lamivudine Prophylaxis
50%
Hepatitis D Virus
50%
Liver Fibrosis
50%
Hepatitis C Virus Genotypes
50%
Fibrosis Marker
50%
Liver Fibrosis Diagnosis
50%
Sustained Virological Response
50%
Urokinase-type Plasminogen Activator
25%
Direct-acting Antiviral Regimens
25%
Tumor Necrosis Factor-α
25%
Interleukin-8
25%
Monocyte Chemoattractant protein-1 (MCP-1)
25%
Patients Included
16%
Medicine and Dentistry
Chronic Hepatitis C
100%
Transient Elastography
90%
Fibrosis
70%
Adverse Event
50%
Hepatitis delta virus
50%
Liver Fibrosis
50%
Antiviral Drug
50%
Liver Cirrhosis
34%
Liver Biopsy
30%
Ribavirin
28%
Antivirus Agent
22%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
50%
Hepatitis delta virus
50%
Chronic Hepatitis C
50%
Antiviral Drug
50%
Lamivudine
50%
Chemotherapy
50%
Diffuse Large B Cell Lymphoma
50%
Antivirus Agent
27%
Ribavirin
18%
